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Introduction
“Vaping” is the inhalation of an aerosolized substance produced through heating a
solution that typically contains nicotine, cannabis, or other substances. There are
many products available commercially used as devices for vaping such as the
electronic cigarette, vape, or “JUUL.” Vaping has become especially popular among
teens and young adults likely due to marketing these devices as “safe” when
compared to the traditional cigarette, and there are a wide variety of flavors.1
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According to the CDC, more than 3.5 million teens reported using e-cigarettes in
2018. The number of vapers globally has been increasing rapidly - from about seven
million in 2011 to 41 million in 2018. The use of vaping products has been associated
with an outbreak of “E-cigarette or vaping product use associated lung injury
(EVALI).” which started in the United States in the summer of 2019. According to the
CDC, as of January 14, 2020, there have been a total of 2668 hospitalized EVALI
cases, reported in all 50 states, with sixty confirmed deaths. While the CDC, FDA,
and state health authorities are still collecting data, research is suggesting that THCcontaining products are most often linked to EVALI cases. Data has also been
collected that suggest Vitamin E acetate is strongly linked to EVALI cases, and the
compound has been found in bronchoalveolar lavage fluid.2
Symptoms of EVALI include3:
Shortness of Breath (85%)
Cough (85%)
Chest pain (52%)
Hemoptysis (8%)
Constitutional Symptoms like Fever (84%) and Chills (60%)
GI symptoms: Nausea (66%), Vomiting (61%), Diarrhea (44%)
.
Patients can present to the emergency department or physician’s office with many of
the above symptoms. Upon examination 58% of people are hypoxemic, fever is
present in 33% of cases, and can be seen with both tachycardia and tachypnea. On
chest x-ray, 83% of patients can be expected to have diffuse hazy or consolidative
opacities.3
Formal diagnostic criteria for EVALI have not been totally established, and the
diagnosis is typically a diagnosis of exclusion. Clinicians should specifically rule out a
lung infection. It is recommended to order testing for Influenza, a viral respiratory
panel, and urine antigen tests for Legionella and S. pneumoniae, in addition to blood
cultures, sputum culture. If HIV is clinically suspected testing for opportunistic
infections is appropriate. Once infection has been ruled out, and alternative
diagnoses (ie cardiac, neoplastic, or rheumatologic) have also been ruled out,
clinicians may then think about a diagnosis of EVALI. Criteria to establish a diagnosis
of EVALI include use of an e-cigarette or related product in the previous 90 days, and
lung opacities on CT or chest x-ray.3.4
Treatment of EVALI has not yet been well established. One study has shown that
approximately 95% of patients with EVALI have required hospitalization. The
mainstay of treatment is supportive care including supplemental oxygen if required
with a target pulse oximetry reading from 88-92%. In most EVALI patients, it is
recommended not to overlook the diagnosis of community acquired pneumonia, co
empiric antibiotics to cover for CAP are recommended.
Systemic glucocorticoids are often used in the treatment of EVALI, though there are
no formal studies. There have been several small scale studies that may show a
benefit of systemic glucocorticoids. Long term effect of EVALI are unknown. With
regards to follow up, it is recommended to follow clinically until resolution of
symptoms. It is also recommended to follow radiographically to ensure resolution of
the illness process.3.4.5
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History
17-year-old male with no significant PMH who presented to Reading
hospital with a nonproductive cough, SOB, chest tightness, vomiting,
diarrhea and fever to 103 at home. Fever did improve with Tylenol at home.
Started with URI symptoms about a week ago which acutely became worse
over the last few days. Seen in ED 4 days prior to admission, CXR at that
time unremarkable, vital signs within normal limits at the time and sent
home with supportive care. Also endorsed pain with deep inspiration. 9/10
severity with deep breaths. Location was over the middle of the chest.
Endorsed daily vaping with tobacco and near daily vaping with Marijuana,
last use 3 days prior to admission. Also endorsed recent weight loss, did not
have exact weight but dropped 4 pant sizes in the last month, however, may
patient believe it may have been due to not playing rugby. NO recent travel,
NO sick contacts, NO animal exposure
ROS – decreased activity level & appetite, fever, chills, unexpected weight
change, congestion, shortness of breath, abdominal pain, and headache
Physical Exam
Vitals : BP 122/72 // Pulse 109 // Temp 38.4C or 101.1F //
RR 48 // SpO2 87% // Wt 57.6kg
Constitutional: Normal appearance.
HEENT: unremarkable, moist mucous membranes without
erythema, exudates or petechiae, tonsils: 2+ and cryptic,
PERRL
Cardiovascular: RRR, no MGR, no chest wall tenderness
Pulmonary: scattered wheezing. Course bibasilar rales
(L>>R), Increased resp effort requiring 02 NC
Abdominal: Soft, nontender, normal bowel sounds in all 4
quadrants
Neurological: Alert and oriented x3, no focal neurological deficit
Skin: warm, no rashes, no ecchymosis

Labs:

131 98 16
4.2 20.5 0.90

94

Anion gap 13
Calcium 9.0
CRP 33.0
Total Protein 7.2 Sed Rate 68
Albumin 3.7
Lactic Acid 0.8
Total Bilirubin 0.7
AST 27, ALT 9, alkaline phosphatase 67

36.5

15.5

12.7

355
MCV 86.3
Lymphocyte% 7.4

Monocyte% 2.3
Neutrophil % 75.9
Eosinophil% 13.6
Basophils% 0.3

Imaging: CXR: Fairly diffuse bilateral infiltrates are now demonstrated
suggesting atypical pneumonia or possibly inhalational lung injury. Pulmonary
edema or hemorrhage is considered less likely.
CT: Extensive, diffusely scattered, and partially consolidated alveolar densities
throughout the upper lungs bilaterally with areas of subpleural sparing.
Negative for pleural effusion, pneumothorax, or pneumomediastinum. Findings
are nonspecific but given clinical history and age vaping associated pulmonary
injury is suspected.

Treatment Course
TIMELINE

09/21/2019: Patient presents to the ED for fever and persistent non-productive cough for a week. Chest x-ray obtained shows no acute
cardiopulmonary activity. Based on reported symptoms etiology thought to be viral illness by ED provider. Patient’s vaping habits were
discussed prior to discharge from the ED
09/23-9/25/2019: Despite follow-up visit with PCP on 09/23 there were multiple telephone encounter between PCP’s office and mother of
patient for persistent fevers, as high as 103 F, dyspnea and excessive coughing with episodes of post-tussive emesis.
09/25/2019: patient returns to the ED febrile, tachypneic, hypoxic and tachycardic. Chest x-ray obtained was significant for diffuse bilateral
infiltrates. Based on chest x-ray atypical pneumonia versus inhalation injury was considered as the etiology. RSV PCR, influenza PCR, blood
and urine cultures were collected, and he was given azithromycin and dexamethasone by ED provider. His SpO2 improved (>92%) with 3L
nasal cannula. Once stable, patient was admitted on the pediatric unit under Family Medicine Residency Service for acute hypoxemic
respiratory failure.
Pulmonary intensivist was consulted. High-Resolution CT chest, streptococcal pneumoniae and Legionella urinary antigens were
ordered by the specialist. CT imaging showed extensive bilateral alveolar/interstitial infiltrates consistent with vaping induced lung injury.
Treatment regimen recommended: azithromycin 250 daily X5 days, prednisone 40 mg daily, DuoNeb q.4hr p.r.n, albuterol q.2hr p.r.n. , and O2
therapy as needed.
9/26/2019: Patient continues to have dyspnea, hypoxemia and tachypnea with minimal exertion. The case was reported to Pennsylvania
Department of Health who then requested that vaping devices and solutions would be sent to DOH for further investigation into the potential
substance abuse substances causing the syndrome.
09/27/2019: Dyspnea and intermittent tachypnea with minimal exertion unchanged. Hypoxemia resolved. Repeat chest x-ray showed
minimal improvement of airspace consolidation.
09/28/ 2019- Day of discharge. Patient continues to have SpO2 greater than 90% on room air. There is resolution of tachypnea with minimal
exertion. dyspnea, lesser intensity when compared to admission, persists. Urinary antigens resulted negative. Blood and urine cultures were
negative. HIV study negative. Patient completed 4/5 days of azithromycin 250 daily prior to discharge. He was discharged with his final dose
azithromycin and prednisone 40 mg to take q.daily until follow-up with Pulmonary outpatient.
10/04/2019- patient evaluated by PCP. No respiratory distress or hypoxia noted. Per chart review, patient continued to have intermittent
episodes of dyspnea with moderate exertion and persistent fatigue. Documented resolution of these symptoms were on 10/28/2019.
10/24/2019- chest x-ray ordered by CHOP pulmonology group. Impression read: “Interval resolution of the bilateral pulmonary opacities. The
lungs are now clear”.

New device on commercial markets. New pathology. Unlike
tobacco and marijuana cigars, the delivery system of the Ecigarettes provides higher concentration of substances at a
higher temperature. Often the oils used as a vehicle for
delivery of THC or nicotine contain other various solvents
and solutions which are not FDA approved. All components,
including THC and nicotine, are aerosolized and delivered
directly into the lung alveoli. In a few of the case reports
available since early 2019 the duration of use to presentation
of symptoms is a range between 6 to 12 months. There were
a few outliers who became symptomatic after 2 years of use.
Severity of presentation various as does length of hospital
stay. Per Characteristics of a Multistate Outbreak of Lung
Injury Associated with E-cigarette Use, or Vaping — United
States, M&M report, the median duration between symptom
onset and hospitalization was 6 days9.
Mechanism of injury to the lung parenchyma is due to
inflammation which isn't a novel concept, but the type
inflammation that predominates the lung parenchyma is
something that is looked at among researchers. Most of the
information available are through case studies where
bronchoscopy was performed and then analyzed. Most
samples were taken from patient's requiring ICU level of
care. On the bronchioalveolar lavage cell count and
differential a strong predominance white blood cells are
noted. Of the leukocytes, almost all samples contained over
50% of neutrophils. A close second in predominance were
macrophages. These macrophages contained lipids. This is
potentially significant since the current theory of
pathophysiology involves the inhalation fat-soluble vitamin E.
Vitamin E is a common additive found within vaping
solutions, most commonly those also containing THC, and
could be a major pro inflammatory component.
What maybe considered a key in vaping induced lung injury is
that bronchioalveolar lavage sample also contained no
significant microbes on H+E. additionally blood cultures on
these patients are often negative. Despite this, when a
patient presents with suspected EVALI what is often provided
in the therapy regimen includes daily corticosteroids,
antibiotics, and respiratory therapies such as albuterol
and/or ipratropium. This is an unsubstantiated regimen, but
for now it’s the temporary standard of care. To date, there is
much about the pathophysiology, efficacy of treatment,
sequela of lung injury that is unknown. Thus, CDC
continues to recommend persons the refrain from using ecigarette, or vaping, products, particularly those containing
THC.
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